Core Viewpoint - The company has signed an investment agreement to acquire a stake in Swiss aesthetic company Suisselle SA, enhancing its strategic relationship and expanding its presence in the global aesthetic market [1][2] Group 1: Investment Details - The investment in Suisselle will allow the company to permanently hold exclusive agency rights for the CELLBOOSTER product in China, strengthening long-term collaboration [1] - The partnership will leverage Suisselle's established platform in Europe to accelerate the promotion and sales of the company's self-developed aesthetic products in European and other overseas markets [1] Group 2: Strategic Expansion - The investment marks a significant step in the company's global strategy for the aesthetic business, completing its strategic layout in the core aesthetic markets of Europe and North America [2] - The company aims to continue driving high-quality aesthetic solutions through a combination of independent research and international collaboration, creating long-term sustainable value for shareholders and investors [2]

Core Insights - Four Seasons Pharmaceutical (00460) has signed an investment subscription agreement to acquire a stake in Swiss medical aesthetics company Suisselle SA, aiming to enhance their strategic relationship and expand in the global medical aesthetics market [1][2] - The company previously secured exclusive agency rights for the CELLBOOSTER water needle in China in 2022, and this investment will solidify their long-term partnership, granting permanent exclusive agency rights for the product [1] - The collaboration will leverage Suisselle's established platform in Europe to accelerate the promotion and sales of the company's self-developed medical aesthetic products in Europe and other overseas markets [1] - The investment aligns with the company's globalization strategy, aiming to build an international medical aesthetics ecosystem covering research, production, and sales [1] Strategic Developments - The company has been actively pursuing a global strategy in the medical aesthetics sector, having fully acquired American medical aesthetics equipment company Genesis Biosystems in 2021, marking its entry into the North American market [2] - The investment in Suisselle represents a critical step in the company's global strategy, completing its strategic layout in the core medical aesthetics markets of Europe and North America [2] - The company plans to continue driving high-quality medical aesthetic solutions through a dual approach of independent research and international collaboration, aiming to create long-term sustainable value for shareholders and investors [2]